Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Lansoprazole sodium
Cat. No.:
0225LY-1296
Appearance:
Solid
Purity:
≥98%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Lansoprazole sodium is a proton pump inhibitor widely utilized to manage gastric acidity in patients with peptic ulcers or gastroesophageal reflux disease.
Synonym:
Lansoprazole (sodium); AG-1749 sodium; 226904-00-3; Lansoprazole (sodium); 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]benzimidazol-1-ide
CAS No.:
226904-00-3
Compound CID:
12044540
Formula:
C16H13F3N3NaO2S
Formula Weight:
391.34
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Lansoprazole sodium can be used in gastroenterology research to study the inhibition of the H+/K+-ATPase pump and its impact on acid secretion.
Library Information
Target:
Proton pump; Phospholipase
Receptor:
Proton pump; Phospholipase
Pathways:
Metabolism; Membrane transporter/Ion channel; Microbiology/Virology
Plate Number:
AOCL-17
Plate Location:
f3
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
60 mg/mL; 153.32 mM
